Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Receivables (2016 - 2025)

Fortress Biotech has reported Change in Receivables over the past 10 years, most recently at $11.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $11.8 million for Q4 2025, up 1674.16% from a year ago — trailing twelve months through Dec 2025 was $19.3 million (up 532.2% YoY), and the annual figure for FY2025 was $19.3 million, up 532.2%.
  • Change in Receivables for Q4 2025 was $11.8 million at Fortress Biotech, up from $2.4 million in the prior quarter.
  • Over the last five years, Change in Receivables for FBIO hit a ceiling of $11.8 million in Q4 2025 and a floor of -$10.4 million in Q2 2023.
  • Median Change in Receivables over the past 5 years was $54500.0 (2021), compared with a mean of $346350.0.
  • Peak annual rise in Change in Receivables hit 14170.59% in 2023, while the deepest fall reached 10538.55% in 2023.
  • Fortress Biotech's Change in Receivables stood at -$8.5 million in 2021, then soared by 99.4% to -$51000.0 in 2022, then skyrocketed by 14170.59% to $7.2 million in 2023, then plummeted by 110.41% to -$747000.0 in 2024, then skyrocketed by 1674.16% to $11.8 million in 2025.
  • The last three reported values for Change in Receivables were $11.8 million (Q4 2025), $2.4 million (Q3 2025), and -$2.8 million (Q2 2025) per Business Quant data.